Exact Sciences Corp (EXAS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Region:North America

Author(s):

Product Code:GDPH56354D

Download Sample Report download
Buy the Full ReportStarting from $250
Published on

November 2018

Total pages

32

Table of Content

Download Sample Report download
Buy the Full ReportStarting from $250

About the Report

About the Report

Summary

Exact Sciences Corp (Exact Sciences) is a molecular diagnostic company that focuses on the early detection and prevention of various types of cancers. The company's flagship product, Cologuard test is a non-invasive stool-based deoxyribonucleic acid (DNA) screening product indicated for the early detection of colorectal cancer and pre-cancer. It utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer. The company is also working on the development of additional tests for other types of cancers and identified proprietary methylation markers for several major cancers. It operates laboratory facilities in Madison, Wisconsin to process Cologuard tests. Exact Sciences is headquartered in Madison, Wisconsin, the US.

Exact Sciences Corp (EXAS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Products

Products

Exact Sciences Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Table of Contents

Table of Contents

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Exact Sciences Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Exact Sciences Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Exact Sciences Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Exact Sciences Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Exact Sciences Corp, Medical Devices Deals, 2012 to YTD 2018 9

Exact Sciences Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Exact Sciences Corp, Pharmaceuticals & Healthcare, Deal Details 11

Venture Financing 11

Biomatrica Raises USD18.1 Million in Financing 11

Partnerships 12

Microbiologics Enters into Licensing Agreement with Biomatrica 12

Licensing Agreements 13

Biomatrica Enters Into Licensing Agreement With ATCC For DNAstable And RNAstable Reagents 13

Equity Offering 14

Exact Sciences Raises USD245 Million in Public Offering of Shares 14

Exact Sciences Prices Public Offering of Shares for USD178.5 Million 16

Exact Sciences Completes Public Offering Of Shares For USD 146.6 Million 17

Exact Sciences Completes Public Offering Of Shares For USD 78 Million 19

Exact Sciences Completes Public Offering of Common Stock For USD 62 Million 20

Debt Offering 21

Exact Sciences Prices Public Offering of 1% Convertible Senior Notes Due 2025 for USD190 Million 21

Exact Sciences Raises USD690 Million in Public Offering of Senior Notes Due 2025 22

Exact Sciences Corp-Key Competitors 23

Exact Sciences Corp-Key Employees 24

Exact Sciences Corp-Locations And Subsidiaries 26

Head Office 26

Other Locations & Subsidiaries 26

Recent Developments 27

Strategy And Business Planning 27

Aug 14, 2018: University Research Park Breaks Ground on Corporate Headquarters Building for Exact Sciences 27

Financial Announcements 28

Oct 30, 2018: Exact Sciences announces third quarter 2018 financial results 28

Jan 07, 2018: Exact Sciences to report USD 265.5-266.5 million in revenue, 168 percent growth for 2017 29

Jul 25, 2017: Cologuard revenue increased to USD 57.6 million during second quarter; Test volume grew 149 percent from second quarter of 2016 to 135,000 completed tests 30

Feb 21, 2017: Exact Sciences reports lower Q4 net loss, provides outlook for 2017 31

Appendix 32

Methodology 32

About GlobalData 32

Contact Us 32

Disclaimer 32


List of Figure

List of Figures

Exact Sciences Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Exact Sciences Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Exact Sciences Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Exact Sciences Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Exact Sciences Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Exact Sciences Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Exact Sciences Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Exact Sciences Corp, Medical Devices Deals, 2012 to YTD 2018 9


List of Table

List of Tables

Exact Sciences Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Exact Sciences Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Exact Sciences Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Exact Sciences Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Exact Sciences Corp, Deals By Therapy Area, 2012 to YTD 2018 8

Exact Sciences Corp, Medical Devices Deals, 2012 to YTD 2018 9

Exact Sciences Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Biomatrica Raises USD18.1 Million in Financing 11

Microbiologics Enters into Licensing Agreement with Biomatrica 12

Biomatrica Enters Into Licensing Agreement With ATCC For DNAstable And RNAstable Reagents 13

Exact Sciences Raises USD245 Million in Public Offering of Shares 14

Exact Sciences Prices Public Offering of Shares for USD178.5 Million 16

Exact Sciences Completes Public Offering Of Shares For USD 146.6 Million 17

Exact Sciences Completes Public Offering Of Shares For USD 78 Million 19

Exact Sciences Completes Public Offering of Common Stock For USD 62 Million 20

Exact Sciences Prices Public Offering of 1% Convertible Senior Notes Due 2025 for USD190 Million 21

Exact Sciences Raises USD690 Million in Public Offering of Senior Notes Due 2025 22

Exact Sciences Corp, Key Competitors 23

Exact Sciences Corp, Key Employees 24

Exact Sciences Corp, Subsidiaries 26

You can also purchase parts of this report.
Do you want to check out a section wise price list?
Get Price Break-up

Why Buy From US?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022